The Breast Surgery theoretical and practical knowledge curriculum comprehensively describes the knowledge and skills expected of a fully trained breast surgeon practicing in the European Union and European Economic Area (EEA). It forms part of a range of factors that contribute to the delivery of high quality cancer care. It has been developed by a panel of experts from across Europe and has been validated by professional breast surgery societies in Europe. The curriculum maps closely to the syllabus of the Union of European Medical Specialists (UEMS) Breast Surgery Exam, the UK FRCS (breast specialist interest) curriculum and other professional standards across Europe and globally (USA Society of Surgical Oncology, SSO). It is envisioned that this will serve as the basis for breast surgery training, examination and accreditation across Europe to harmonise and raise standards as breast surgery develops as a separate discipline from its parent specialties (general surgery, gynaecology, surgical oncology and plastic surgery). The curriculum is not static but will be revised and updated by the curriculum development group of the European Breast Surgical Oncology Certification group (BRESO) every 2 years.

No abstract

No abstract

No abstract

Background: Breast cancer screening has always been a challenging task in underdeveloped countries like Pakistan. We believe that during this era precision medicine for breast cancer is the most accurate approach in prevention, diagnosis and treatment of the disease. Several kinds of genetic and nongenetic tests for breast cancer are available that can help personalised therapy. Our study aims to find the role of precision medicine in breast cancer screening.Materials & Methods: The study was conducted in Sir GangaRam Hospital, Lahore. 500 patients were included in the study. Informed consent was obtained. For our risk-based screening approach, we selected the Breast Cancer Surveillance Consortium (BCSC) model. Variables typically include demographics (age, race/ethnicity), reproductive history, menopausal status, family history, breast biopsies, benign breast disease, single nucleotide polymorphisms and mammographic density.Results: The Breast Cancer Surveillance Consortium risk model will be used to calculate a woman's 5-year risk and will be modified by a polygenic risk score based on 76 SNPs. For women age 40 to 49 years, screening is recommended when their five-year risk equals or exceeds that of the average woman age 50 years. Women will be recommended to go for annual screening due to the precipitating factors such as dense breast or oestrogen receptor negative breast cancer. Carriers of genetic mutations will receive screening recommendations guided by their mutation type and family history.Conclusion: Our main goal is early detection and prevention of cancer. Personalized screening may be the way forward in preventing breast cancer, but this can only be determined within the setting of a randomized controlled trial. We have provided the evidence base underlying our proposed risk assessment process and the risk thresholds used to inform individualized screening recommendations.No conflict of interest.